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© 2011 Japanese Society of Tropical Medicine Abstract: Pathogenic viruses have RNA genomes that cause acute and chronic infections. These viruses replicate
with high mutation rates and exhibit significant genetic diversity, so-called viral quasispecies. Viral quasispecies
play an important role in chronic infectious diseases, but little is known about their involvement in acute infectious
diseases such as dengue virus (DENV) infection. DENV, the most important human arbovirus, is a causative agent
of dengue fever (DF) and dengue hemorrhagic fever (DHF). Accumulating observations suggest that DENV exists as
an extremely diverse virus population, but its biological significance is unclear. In other virus diseases, quasispecies
affect the therapeutic strategies using drugs and vaccines. Here, I describe the quasispecies of DENV and discuss
the possible role of quasispecies in the pathogenesis of and therapeutic strategy against DENV infection in
comparison with other viruses such as Hepatitis C virus, human immunodeficiency virus type 1, and poliovirus.
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The genome of RNA viruses, including dengue virus,
rapidly accumulates mutations because of the error-prone
nature of RNA polymerase [1, 2], resulting in variations of
the virus genome, so-called quasispecies. This diversifica-
tion leads to fitness or loss due to the deleterious mutation
or rapid and unpredictable fitness gains [3]. Although this
genetic variation is produced by mutation, it could reflect
the process of natural selection. In quasispecies of virus
infections, the two key terms are “random mutation” and
“selection.” Mutations are introduced by random mutation,
and the produced virus population is influenced by the host
environment, which causes the selection of virus.
Quasispecies play a critical role in the progression of
chronic infectious diseases such as Hepatitis C virus (HCV)
and human immunodeficiency virus type 1 (HIV-1) [4–6].
With respect to acute infectious diseases such as dengue
virus or influenza virus infections, the biological relevance
of quasispecies in pathogenesis remains unclear although
there is accumulating circumstantial evidence showing that
these viruses also exist as quasispecies. One of the reasons
is the difficulty in monitoring the diversity of viruses during
such a short course of acute infection.
In this review, I discuss the virus quasispecies of
DENV with reference to other RNA viruses because little
information is available on quasispecies of DENV, while,
on the contrary, several studies on other viruses demon-
strated the biological relevance of quasispecies, for example,
escape of HIV-1 and HCV from immune pressure and drug
treatment, and their effects on poliovirus pathogenesis [7].
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2. DENV INFECTION
DENV, the most important arbovirus for humans, is the
pathogen of dengue fever (DF) and dengue hemorrhagic
fever (DHF), the latter being the more severe form of the
disease [8]. It is estimated that there are 50–100 million
cases of infections and more than 2.5 billion people are at
risk [9]. DENV is highly restricted in its natural host range
transmitted between humans and mosquitoes [10].
DENV belongs to the genus Flavivirus of the family
Flaviviridae, which are positive-sense, single-strand RNA
viruses. The viral genome is approximately 10,700 bases in
length. Its single polyprotein is produced from one long
open reading frame, from which individual proteins are
produced by cleavage of cellular and viral proteases [11].
The genome encodes three structural proteins (capsid [C],
premembrane [preM/M], and envelope [Env]) and seven
non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A,
NS4B, and NS5). There are four serotypes (DENV 1–4). All
four DENVs are responsible for severe disease. Infection
with one serotype of DENV leads to life-long protection
against homologous serotypes of DENV but only temporary
protection against heterologous infection with a different
serotype [12]. Epidemiological observations indicate that
90% of DHF cases occur during secondary heterologous
DENV infection and that the risk of DHF is highly increased
in secondary infection [13]. The unique feature of DENV
infection is the antibody-dependent enhancement (ADE) of
virus infection [14], which explains why most severe
cases occur in secondary infection. The pre-existing non-
neutralizing antibodies against different serotypes of
DENV, which were obtained in previous infection with
other serotypes of DENV, bind to heterologous DENV and
enhance viral entry into FcR-bearing target cells such as
monocytes [15].
3. QUASISPECIES OF RNA VIRUSES
Viruses with RNA genome are the most abundant
group of human, animal and plant pathogens. Unlike DNA
polymerase, RNA viruses lack proofreading activity,
resulting in an error rate during replication that is estimated
to be 10
−3 to 10
−5 mutations per nucleotide per replication
cycle[16, 17]. An acutely infected organism harbors 10
9 to
10
12 viral population at any given time. With an RNA
virus genome length of approximately 10
4 nucletides, every
possible single mutant and many double mutants are likely
to occur. Although most mutant viruses are probably defec-
tive, the produced virus population potentially contains
diverse viruses. RNA viruses cause both acute and chronic
infections. It is understandable that viral quasispecies play
an important role in chronic infectious disease, because the
course of these diseases is long, sometimes lasting for
decades. When confronting the host immune system, these
viruses change their genomic information, and as a result,
enhance the possibility of producing mutant viruses. On the
other hand, viruses causing acute infections have less
chance to produce mutant viruses. However, recent reports
suggest the importance of quasispecies in acute viral infec-
tious diseases [7, 18]. Moreover, it was recently reported
that quasispecies at the early stage of disease were a
determinant of severity even for chronic infectious diseases
such as HIV-1 and HCV [4, 19–21]. Studies on acute infec-
tious diseases from this aspect have been just started, even
though the concept of quasispecies was proposed more than
thirty years ago [22].
4. THE ROLE OF VIRAL QUASISPECIES IN THE 
ESCAPE FROM IMMUNE RESPONSE, THERAPEUTICS, 
AND VACCINES
4-1. The role of viral quasispecies in the escape from the
host immune response
There are accumulating reports demonstrating the
important role of quasispecies of other RNA viruses in the
progression of disease. Two well-studied examples are
HCV and HIV-1 [4–6]. HCV, the cause of hepatitis C in
humans, belongs to the genus Hepacivirus within the family
of Flaviviridae and is also known to exist as quasispecies. It
causes a chronic infection, but the viral quasispecies of
HCV at the acute phase of infection determine the course of
disease progression [4, 19, 20]. The specific humoral and
cellular immune response clear HCV until all the variants
are effectively eliminated from the patient’s body. However,
when the host immune system fails to reduce the genetic
diversity of HCV quasispecies, HCV continuously escapes
from the immune response [23]. In case of infection with
HIV-1, the quasispecies of HIV-1 play an important role in
the escape from the host immune response [21]. The control
of the genetic diversity of these viruses during the first few
months after infection determines the progression of disease
[4, 21, 24, 25]. Even in chronic infection, a key factor is the
increase of the virus population size at the acute phase of
infection. Otherwise, these viruses would fail to escape
from the immune response during the chronic phase.
On the other hand, it remains unclear whether viral
quasispecies play an important role in acute infections.
DENV infection, however, is not simply an acute infectious
disease, because it has four serotypes and the infection is
enhanced by pre-existing non-neutralizing antibodies as
described above. In the case of secondary infection, some
pre-existing antibodies partially inhibit viral infection, but31 T. Kurosu
other antibodies may enhance infection through ADE. The
balance between neutralization and ADE is probably a key
factor determining severity by controlling the production
of DENV (Fig. 1). We observed that DENV-2 derived
from patients with primary infection were heterogenous,
while on the other hand, DENV-2 derived from patients
with secondary infection were homogenous (unpublished
observation). This result suggests that the homogenous
population of DENV-2 may be the result of selection by
ADE (Fig. 2). That is, the DENV-2 may be positively
selected by non-neutralizing pre-existing antibodies derived
from previous infection with other serotypes of DENV.
Otherwise, this homogenous virus might be able to success-
fully escape from the immune system. Although the mecha-
nism of selection is unknown, our observation suggests that
DENV quasispecies affects the progression of disease,
especially in secondary infection.
4-2. Effects of viral quasispeceis on drugs
Antiretroviral therapy, known as “highly active anti-
retroviral therapy” (HAART), which use a cocktail of three
or more drugs working together to fight HIV, has led to a
dramatic reduction in mortality and significant improve-
ment in the quality of life of HIV-1-infected patients [26–
29]. However, side effects, the requirement for strict
Fig. 1.  A) Diversity of pre-existing antibodies and DENV. In DENV-infected patients with secondary infection, the diverse antibody
population and the diverse DENV population exist at a very early stage of infection. B) Pre-existing neutralizing antibodies
block DENV infection. On the other hand, non-neutralizing antibodies enhance DENV infection through ADE. DENV infection
is positively and negatively regulated by pre-existing antibodies.
Fig. 2.  Hypothetical mechanism of DENV infection. DENV
present as a heterogenous population at an early phase
of infection. The parts of DENV are positively selected
by non-neutralizing/enhancing antibodies. Homogenous
DENV population is predominantly produced at the
peak of infection.32 Tropical Medicine and Health Vol.39 No.4 Supplement, 2011
adherence and the fact that HAART does not completely
inhibit residual replication of HIV-1, can lead to therapy
failure. It is extremely important that patients take medicines
and do not miss doses. If they do not, the uncontrolled usage
of drugs allows the development of a drug-resistant mutant
virus due to quasispecies of HIV-1. A number of studies
have reported the presence of homogeneous HIV-1 qua-
sispecies during primary infection [6, 30–32], while others
have suggested that a heterogeneous viral population may
predominate during the early period [11, 33, 34]. In recent
years, most researchers believe that HIV-1 produces a
heterologous virus population at the early phase of infec-
tion. The disparity among these reports is probably due to
the different detection methods or sensitivity of each
protocol. Although the fittest virus rapidly outgrows other
populations during the early stages of acute infection and
goes on to establish a homogenous virus quasispecies HIV-1,
it is clear that drug-resistant viruses sooner or later emerge
by selection after starting medication. Subsequently, the
drug-resistant mutant virus becomes the major presence in
the virus population and causes the death of the patient.
More importantly, drug resistant viruses have the potential
to infect other HIV naïve persons because they are already
drug-resistant at the outset of infection. In this case, the
drug-resistant mutant progressively produces viruses from
the beginning of anti-virus therapy.
Another drug-resistant pathogen is the antibiotic resis-
tant bacterium. Antibiotic resistance poses a significant
problem. The prevalence of antibiotic-resistant bacteria is
the result of antibiotic use. As resistance becomes more
common, there is a greater need for alternative treatments.
However, the development and approval of new drugs does
not easily catch up with the mutant bacterium. Even for
acute viral infectious disease, the appearance of drug-
resistant mutants is a serious problem, as shown by the
antiviral-resistant influenza virus.
Although an antiviral drug ‘to combat’ DENV has not
been developed yet, these examples suggest a need to
develop several types of anti-DENV drugs. Also, patients
should be treated with several drugs at the same time in
order to prevent the emergence of drug-resistant mutant
viruses.
4-3. Effects of viral quasispecies on the development of
vaccines
A similar situation may occur when vaccines are
developed to combat viruses. Because of their high muta-
tion rates, these viruses frequently develop a resistance to
vaccines similar to that seen in the application of antiviral
drugs [35–39].
There are several ongoing vaccine projects, but no
DENV vaccine has been licensed to date. The tetravalent
live-attenuated chimeric vaccine seems to be the most
promising. These vaccines mainly target the surface mole-
cules of DENV particles, pre-membrane (prM) and envelope
(Env) proteins of the four serotypes of DENV. They are
based on one strain of each serotype of DENV. If DENV is
genetically stable, the vaccine will exert its maximum
effect. However, DENV quasispecies found in mosquitoes
and some substitutions potentially change the conformation
of Env protein [40], indicating the possible escape from the
host immune system. If this is the case, it may be difficult to
develop an effective DENV vaccine because a vaccine
against limited strains may be unable to fight a diverse
DENV population. Efforts to develop effective vaccines
must overcome the complex evolutionary dynamics in
DENV-infected individuals and within affected populations.
Quasispecies of DENV have to be more clearly investigated
for effective vaccine development, and the candidate
vaccines need to be studied from this point of view.
Also, quasispecies exert an effect on the vaccine itself.
The most promising DENV vaccine is a chimeric vaccine
constructed using the live-attenuate yellow fever virus
vaccine YFV 17D strain [41, 42]. It should be noted that
this vaccine carries the risk of producing a revertant virulent
virus because of the error-prone nature of RNA polymerase
in the live-attenuate vaccine. Originally, most live-attenuated
vaccines were established from virulent viruses by passage
in cell culture through the introduction of mutation. It is not
be surprising that they might revert to a virulent state in
the future, even though their genomes are relatively stable
compared with wild-type virus. Increasing the fidelity of
genome replication may paradoxically attenuate the virus,
but there is no report focusing on the fidelity of DENV
polymerase. Further detailed studies are needed for the
development of a safe and stable vaccine.
5. THE ROLE OF VIRAL QUASISPECIES 
IN PATHOGENESIS
Quasispecies play a positive role in the escape from
immunological pressure and from the pressure of drug
treatment as discussed above. They may be also involved in
the progression of disease and pathogenesis. Since effect of
the quasispecies of DENV on pathogenesis has not been
reported yet, I will discuss the effect of the quasispecies of
other viruses on pathogenesis. A report on the pathogenesis
of poliovirus using a mouse model system indicates that
quasispecies play an important role in the progression of
the disease [7]. Poliovirus, the causative agent of paralytic
poliomyelitis, starts by infecting lymphoid tissues of the
pharynx and gut, leading to a viremia that may result in an33 T. Kurosu
invasion of the central nervous system (CNS) [43]. In the
CNS, poliovirus replicates in motor neurons within the
anterior horn of the spinal cord, the brain stem, and the
motor cortex. By destroying these cells, it produces the
characteristic paralysis in approximately 1%–2% of all
infections [44]. Within the infected individual, viral replica-
tion occurs in a limited number of cells and tissues. This
host range restriction is determined at the level of the cell
receptor [43]. Vignuzzi et al. first found a mutant poliovirus,
which was resistant to the anti-viral drug ribavirin and
carried “super-accurate” high-fidelity polymerase [7]. Wild-
type poliovirus lethally infects mice by intramuscular injec-
tion. In the final disease stage, the virus invades the brain
and causes mortal infection. Although, the super-accurate
mutant poliovirus showed similar replication kinetics to
the wild-type virus, the “super-accurate,” poliovirus lost its
lethality. Next, the authors created an artificially expanded
quasispecies from the super-accurate mutant poliovirus by
treating virus stock with chemical mutagens. Interestingly,
this virus population reached the mouse brain and caused
death by intramuscular injection. This observation is pre-
dictable because a diverse virus population has a better
chance to overcome the blood-brain barrier (BBB). A muta-
tion may confer a different cell (tissue) tropism on viruses
and enable them to invade the BBB and replicate in the
brain. If this is the case, the brain-adapted viruses would
be found in the mouse brain. However, the above authors
found a major population of virus, namely the super-
accurate poliovirus. More importantly, when the virus
isolated from the brain was injected into mice, it lost its
virulence. Their observation provides direct evidence for
complementation between members in the quasispecies. It
also indicates that selection indeed occurs at the population
level rather than on individual variants. Although the detailed
mechanism of invasion by poliovirus into the CNS is still
unclear, the complexity of the viral quasispecies enabled
the virus population to spread systemically and successfully
access the CNS, perhaps through the complementary func-
tion of different subpopulations.
Taken together, these data support a concept in quasi-
species theory, namely that the successful colonization of an
infected host occurs through the cooperation of different
virus variants. This type of positive cooperation may also
occur during coinfection of a given host with different
viruses, which leads to profound consequences in the patho-
genic outcome of an infection. In the case of DENV infec-
tion, is likely that coinfection occurs very often [45]. Next,
I will discuss the coinfection of DENV.
6. WHAT SUPPORTS QUASISPECIES?
6-1. Coinfection
To deeply understand the concept of DENV quasispe-
cies, we need to understand how quasispecies are main-
tainedin virus population. A coinfection of different viruses
carrying different genetic information is one of the impor-
tant factors. Two different or even several types of DENV
possibly infect into a single cell. It is thought that a large
number of defective viruses are produced in a single host
since most mutations are deleterious. In addition, the
diverse virus population also contains low-fitness intact
viruses, which may be able to show higher fitness in different
environments. These viruses could survive by coinfection
with high-fitness viruses even if they have a disadvantage in
viral replication in the current environment. The long-term
transmission of defective DENV by coinfection has been
proven. Aaskov et al. reported that a defective virus, after
acquiring a stop-codon mutation in the surface Env protein
gene, was transmitted from Myanmer to New Caledonia
and Singapore within a few years. Moreover, this defective
virus was found in both humans and mosquitoes, suggesting
epidemic circulation. Coinfection provides the capacity to
maintain a broad range of diversity in the virus population.
6-2. Memory of quasispecies
Another important concept is the memory genomes of
RNA viruses. A viral quasispecies is defined by a master
sequence and a mutant spectrum. The master sequence is
the dominant nucleotide sequence in the genomic distribu-
tion. It may coincide with the consensus or average sequence
of the virus population. It is usually transmitted to other
hosts and plays a major role in the evolution of viruses. On
the other hand, there is no explanation as to the survival or
transmission of minor virus populations such as the small
population of quasispecies. However, Ruiz-Jarabo et al.,
provided direct evidence for the presence of minor popula-
tions among major virus population, which was thought to
carry a homogenous single virus genome using foot-and-
mouth disease virus [46]. They also showed later that the
minority memory genome of virus potentially influenced
the evolution of multidrug-resistant HIV-1 in patients [47].
This is an important observation, suggesting as it does two
points regarding quasispeceis. Firstly, the authors demon-
strated that viruses could carry the minority memory genome
in their virus population at the intrahost level as well as the
interhost level, although this was maintained at a level
undetectable by conventional protocols. Secondly, their
observations suggested that the virus population, as quasi-
species, carries the historical background, that is to say,
molecular memory genome. For example, a virus popula-34 Tropical Medicine and Health Vol.39 No.4 Supplement, 2011
tion which experienced anti-viral drug treatment may main-
tain the drug-resistant virus even in the absence of the anti-
viral drug.
There is a report which may be related to the memory
genome of DENV. Kinoshita et al. isolated two different
DENVs with different cell tropisms from a single patient,
suggesting the co-circulation of these viruses [48]. One iso-
late was B-cell tropic, even though B-cell is not thought to
be a target of DENV. DENV showing B-cell tropism may be
an example of the memory genome of DENV. At some
point, this DENV population may have encountered an
environment which provided an advantage to the B-cell
tropic minor population of DENV. We have not completely
determined what organ can be a target of DENV, although
monocytes/macrophages are thought to be the main targets.
This observation suggests that the DENV “population” repli-
cates in B-cells.
In this section, coinfection and memory of quasispecies
are discussed. Both are necessary to maintain the quasispecies
of a virus population. It remains unclear how the memory
genome of minor population is maintained, but coinfection
is probably one of the mechanisms by which viral quasispecies
are maintained. The concept of molecular memory genome
is important. If the genome of a minor population of DENV
is maintained through infection in several hosts including
both mosquitoes and humans, the DENV population may
contain various minor populations. When persons who lack
a normal immune system, such as infants and AIDS patients,
are infected with DENV, the DENV population may come
to carry unique genomes, because the immune system is
also a factor affecting tissue/cell-tropisms in addition to
virus receptor on host cells. An intensive study of DENV
quasispecies may reveal the history of the DENV popula-
tion and provide a new vision for the understanding of virus
infection and transmission.
7. QUASISPECIES OF DENV
Studies on quasispecies of DENV by several groups
have revealed that DENV is a swarm of mutant viruses [40,
49–52]. These studies analyzed intrahost sequence diversity
of the Capside, Env, and NS2B, but none identified any
particular amino acid substitution associated with disease
severity. This is understandable because the virulence of
DENV is still unknown. One reason why none of the studies
has clarified the DENV gene associated with virulence is
that the outcome of disease, that is, severity, is due to the
interaction or battle between DENV and the host immune
system. Although the interaction between pathogen and
host is always important, it is particularly important in
DENV. Severe symptoms have been observed when the
host eliminates DENV, suggesting that these symptoms are
due to the protective host reaction. In terms of disease
severity, most researchers have assumed that high virus titer
is associated with severity [53]. Nevertheless, it remains
unclear what viral genome among quasispecies contributes
to the higher viral titer in patients. Even though no evidence
showing that quasispecies of DENV affect pathogenesis, is
currently available, there is logical evidence. DENV from
primary infection and from secondary infection presumably
have different features of intrahost sequence diversity
because DENVs are subjected to different types and levels
of immune pressure between primary and secondary infec-
tions. In addition, the DENV population may be under
positive selection through ADE in secondary infection. That
is, pre-existing antibodies negatively and positively regu-
lated the production of DENV in secondary infection. Like
other groups, we observed the various Env gene sequences
of DENV from single patient (unpublished observation),
suggesting their involvement in the interaction between virus
particles and antibodies.
One important question is whether only one major
population of DENV is transmitted between humans and
mosquitoes [10] The quasispecies of DENV is maintained
during transmission because a diverse DENV population
was observed in both mosquitoes and humans [40]. DENV
presumably always exists as quasispecies and gradually
changes its population during transmission to other hosts.
8. METHODOLOGICAL PROBLEMS ENCOUNTERED 
IN STUDIES ON QUASISPECEIS OF DENV
Although the quasispecies concept was proposed by
Eigen 30 years ago [22], no intensive study has been
conducted on viral quasispecies, especially acute infectious
diseases such as DENV. This is partly due to methodological
problems. As described above, the minor virus population
is thought to account for a very low percentage of the
DENV population. To detect the minor virus population, the
genes have to be analyzed by gene cloning, which requires
much more time-consuming work than direct sequencing. If
the minor population accounts for one percent of the virus
population, at least 100 clones have to be analyzed. Another
problem is selection or adaptation of virus to cultured cells
during virus isolation. Thus, methodological problems are
obstacles for the detailed analysis of quasispecies. However,
a recent technological improvement in sequencing may
allow a breakthrough in studies on quasispecies. The ultra-
deep method facilitated by 454 Sequencing and other new
systems offers dramatically improved sensitivity in detect-
ing low-frequency viral variants, which means minor popu-
lations of viral quasispecies, compared to traditional35 T. Kurosu
population-based sequencing methods. Further studies using
thge new technologies are necessary to shed light on the
physiological relevance of DENV quasispecies.
9. CONCLUSION
Studies on quasispecies of viruses causing acute infec-
tious diseases such as DENV have only just started. It is
now clear that DENV exists as quasispecies. What is less
clear is whether individual populations contain viruses that
differ in important phenotypic properties and what propor-
tion of DENV genomes are defective. Detailed studies on
quasispecies of DENV will assist the development of anti-
DENV strategies such as antiviral drugs and vaccines.
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